Rose covers disability and mental health, and she helps write STAT’s daily Morning Rounds newsletter. Confidential tips can be sent to Rose on Signal at rosebroderick.11. Scroll through the flashy ...

Seven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs ...

Commure, a $7 billion health software company that sells artificial intelligence tools to medical clinics, has terminated a program through which it was paying parties for referrals to new customers, ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

When it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus. Such is the case with a therapy from Neurocrine Biosciences.

Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer ...

New technologies, cancer doctors, and reproductive specialists are working to give more patients a chance to have children post-treatment.

Young adults’ use of vapes and cannabis hit all-time highs last year, according to the results of a large new national survey conducted at the University of Michigan. The percentage of young adults ...

I have spent much of my career responding to infectious diseases in places where vaccines were desperately needed but not always available. In Haiti, I watched a patient die of tetanus, their body ...

Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer ...

Talks are underway between the Democratic Republic of the Congo and the WHO to expedite the start of a multi-armed Phase 3 clinical trial of Ebola vaccines.

The White House's order attempting to overhaul the vaccine schedule could subject children to more needles and more disease risk, world health leaders say.